{
  "docId": "019de074-640b-7614-ba57-564b2e029ae4",
  "docSlug": "dcb04f24edfbf49f2d2db8f66e75d66c",
  "documentTitle": "Sarissa Capital | Activist Presentation Deck | 109 slides",
  "authorId": "sarissa-capital",
  "authorName": "Sarissa Capital",
  "documentKindSlug": "activist-deck",
  "documentKindLabel": "Activist deck",
  "sourceTypeSlug": "activist_investor",
  "sourceTypeLabel": "Activist investor",
  "presentationDate": "2023-02-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 26,
  "pageCount": 109,
  "prevPage": 25,
  "nextPage": 27,
  "slideType": "expose_contradiction",
  "function": "expose_contradiction",
  "density": "balanced",
  "nDataPoints": 0,
  "notes": "Uses a bomb icon to symbolize the 'lurking' threat.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de074-640b-7614-ba57-564b2e029ae4/26",
  "deckHref": "/decks/019de074-640b-7614-ba57-564b2e029ae4",
  "deckJsonHref": "/decks/019de074-640b-7614-ba57-564b2e029ae4.json",
  "deckAnchorHref": "/decks/019de074-640b-7614-ba57-564b2e029ae4#slide-26",
  "components": [
    {
      "bbox": {
        "h": 0.15,
        "w": 0.6,
        "x": 0.07,
        "y": 0.67
      },
      "kind": "callout",
      "text": "The potential for a third and fourth generic entrant, FDA approved in September 2020 and June 2021 respectively, was clear to even Amarin",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "935ad191-feb0-4b08-9641-7cdac8bd7578",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.2,
        "x": 0.73,
        "y": 0.68
      },
      "kind": "image",
      "text": null,
      "attrs": null,
      "subkind": "illustration",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ef434792-33d3-4c7d-8d4a-6b403593000f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.92,
        "x": 0.07,
        "y": 0.42
      },
      "kind": "paragraph",
      "text": "On May 22, 2020, Hikma received U.S. FDA approval to market its generic version of VASCEPA for the MARINE indication of VASCEPA. In November 2020, Hikma launched their generic version of VASCEPA on a limited scale. On August 10, 2020, Dr. Reddy's received U.S. FDA approval to market its generic version of VASCEPA for the MARINE indication of VASCEPA. In June 2021, Dr. Reddy's launched its generic version of VASCEPA with labeling that is substantially similar to labeling of the Hikma generic product. On September 11, 2020, Teva Pharmaceuticals USA, Inc's, or Teva's, abbreviated new drug application, or ANDA, was approved by the U.S. FDA and on June 30, 2021, Apotex, Inc's, or Apotex's, ANDA was approved by the U.S. FDA.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7bf9636d-538d-4111-82c5-9c5104706d21",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.25,
        "x": 0.07,
        "y": 0.33
      },
      "kind": "source-note",
      "text": "Amarin 10-Q (November 2021)",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4169f143-1b80-446c-a29d-eac4617a6829",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.75,
        "x": 0.07,
        "y": 0.05
      },
      "kind": "title",
      "text": "Amarin was fully aware of additional, potential (3rd and 4th) generic launches lurking",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a9afb32b-a3ee-49f0-b2d5-7c13cedcb197",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "ceo-quote-contradiction",
      "slug": null,
      "matchId": "4c77efe7-20e7-4b14-bceb-626ecd8c5bb5",
      "evidence": "Uses company's own regulatory filings to contradict their narrative.",
      "confidence": 0.9
    }
  ],
  "arcBeats": [
    {
      "to": 63,
      "from": 14,
      "beatId": "98f8728e-8e6f-4524-abbe-b936d0ae5c62",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Agitate",
      "beatSlug": "problem-agitate-solution-agitate-make-it-worse",
      "evidence": "The deck agitates the problem by highlighting Amarin's poor management decisions and lack of alignment with shareholder interests",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": "Development",
      "parentBeatSlug": "development"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}